Company Paradigm Biopharmaceuticals Limited
Equities
PAR
AU000000PAR5
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.28 AUD | 0.00% | +12.00% | -34.12% |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Drugs
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -40.98% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -40.98% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Rennie
CEO | Chief Executive Officer | - | 14-05-01 |
Abby Macnish
DFI | Director of Finance/CFO | - | 22-08-29 |
Jill Forrest
CTO | Chief Tech/Sci/R&D Officer | - | - |
Melanie Duiker
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Ravi Krishnan
CTO | Chief Tech/Sci/R&D Officer | - | - |
Donna Skerrett
CTO | Chief Tech/Sci/R&D Officer | - | 19-08-31 |
Simon White
IRC | Investor Relations Contact | - | 19-12-31 |
Corporate Officer/Principal | - | - | |
Karla Knower
LAW | General Counsel | - | - |
Corporate Officer/Principal | - | 20-10-12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Donna Skerrett
CTO | Chief Tech/Sci/R&D Officer | - | 19-08-31 |
Paul Rennie
CEO | Chief Executive Officer | - | 14-05-01 |
Amos Meltzer
BRD | Director/Board Member | 58 | 20-12-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 351,495,841 | 304,232,313 ( 86.55 %) | 0 | 86.55 % |
Company contact information
Paradigm Biopharmaceuticals Ltd.
500 Collins Street Level 15
3000, Melbourne
+
http://www.paradigmbiopharma.comSector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.12% | 62.49M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- PAR Stock
- Company Paradigm Biopharmaceuticals Limited